This 2024 paper is a narrative review of cannabidiol, cannabis-derived products, regulation, pharmacology, and clinical use. It offers a useful overview of why purified CBD, commercial extracts, and broader cannabis products should not be treated as interchangeable. Its value is real, but it remains a narrative review, not a new trial, so its conclusions should be read as framing and synthesis rather than definitive proof.
This narrative review examines whether the endocannabinoid system may play a biochemical role in ADHD pathophysiology. It gathers 11 preclinical and 2 clinical studies and argues that ECS signaling may intersect with attention, impulsivity, and hyperactivity pathways. The core limitation is that the evidence remains thin, heavily preclinical, and far from proving that cannabinoid-based treatments are ready for clinical use in ADHD.
Medicinal plants in the management of muscle loss and sarcopenia: A narrative review of preclinical and clinical evidence from eight species.
Muscle loss, whether due to aging (sarcopenia), chronic disease, or disuse, is a major contributor to frailty, reduced mobility, and diminished quality of li…